Changes Of Monocyte Chemoattractant Protein-2 And Interleukin-12 Level In Serum Of Patients After Allogeneic Hemapoietic Stem Cell Transplantation And Their Correlation With Acute Graft Versus Host Disease

[Objective]This study aimed to explore the changes of monocyte chemoattractant protein-2(MCP-2) and Interleukin-12(IL-12) level in serum of patients underwent allogeneic hemapoietic stem cell transplantation(allo-HSCT) as well as their correlation with acute graft versus host disease (aGVHD).[Methods]ELISA was used to detect serum level of MCP-2 and IL-12.Twenty patients underwent allo-HSCT(experimental group) and 16 underwent autologous hemapoietic stem cell transplantation(control group) were enrolled in this study.Samples were collected on 14 days, 1 day before hemapoietic stem cell infusion,then every week until the 8 weeks after transplantation. In patients with aGVHD, Samples were taken twice a week. [Results]1.The MCP-2 and IL-12 levels in serum demonstrated no significant difference between -14d and -1d in both experimental and control groups (P>0.05).2.The MCP-2 and IL-12 levels in serum demonstrated no significant difference between +7d and -1d in both groups(P>0.05).3.The aGVHD patients in the experimental group demonstrated aGVHD clinical symptom between +16 to +52d, with their first serum level increase earlier than that of +7d. The average time interval was (6.2±2.4)d for the first increase of MCP-2 level to the clinical symptom, with the maximum of 10d and the minimum of 4d. The average time interval was (4.7±1.3)d for the first increase of IL-12 level to the clinical symptom, with the maximum of 7d and the minimum of 3d.4.Six patients in experimental group happened aGVHD, including 3 aGVHDⅠ-Ⅱs, 3 aGVHDⅢ-Ⅳs. The diagnosed MCP-2 and IL-12 levels in serum demonstrated a significant increase compared with that of the +7d level for those patients (P<0.05), while this indicator also demonstrated a significant decrease after anti-aGVHD treatment relief (P<0.05), still a slight higher than that of the +7d level with little significant difference (P>0.05).5.The time interval of first MCP-2 increase in serum was +11～+46d for aGVHD patients in the experimental group, significantly higher than that of those in the control group (P<0.05). The time interval of first IL-12 increase in serum was +11～+49d for aGVHD patients in the experimental group, significantly higher than that of those in the control group (P<0.05).6.Compared to theⅠ-Ⅱs aGVHD patients, the Serum MCP-2 and IL-12 level ofⅢ-Ⅳs aGVHD patients were higher.7.The serum MCP-2 and IL-12 level demonstrated no significant difference between the 2-8w and the 1d before hemapoietic stem cells infusion in the non-aGVHD patients (P>0.05).8.In the experimental group ,compared to the without infection aGVHD patients, the non-aGVHD patients without infection serum MCP-2 and IL-12 level had no obvious difference (P>0.05).[Conclusions]1.The time of serum MCP-2 and IL-12 level changed was earlier than that of clinical symptoms demonstrated in the aGVHD patients group.The detection of serum (MCP-2 and IL-12) was help to the early prediction of aGVHD.2.Serum MCP-2 and IL-12 level of aGVHD patients is higher than that of non-aGVHD group patients and the control group patients. Serum MCP-2 and IL-12 level changes paralleled aGVHD symptoms change. when the symptom occurred, the level of Serum MCP-2 and IL-12 increased; when the symptom improved , the level of Serum MCP-2 and IL-12 dropped significantly. It suggested that there was a relationship between serum level of MCP-2 and IL-12 and the presentation of aGVHD. The detection of serum MCP-2 and IL-12 is help to the early diagnosis of aGVHD.3.Compared to the mild aGVHD patients, MCP-2 and IL-12 level in Serum of severe aGVHD patients were higher, indicating that MCP-2 and IL-12 levels may be related to the severity of aGVHD.4.Pretreatment, hemapoietic stem cells infusion, infections would not affect the serum MCP-2 and IL-12 level of aGVHD patients.